The stock of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) is a huge mover today! The stock decreased 3.00% or $0.19 on November 30, hitting $6.14. About 73,771 shares traded hands or 101.22% up from the average. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) has declined 30.21% since April 27, 2016 and is downtrending. It has underperformed by 35.44% the S&P500.
The move comes after 6 months negative chart setup for the $84.37M company. It was reported on Nov, 30 by Barchart.com. We have $5.83 PT which if reached, will make NASDAQ:ORMP worth $4.22 million less.
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Ratings Coverage
Out of 3 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Oramed Pharmaceuticals has been the topic of 5 analyst reports since August 14, 2015 according to StockzIntelligence Inc. Zacks upgraded the stock to “Sell” rating in Friday, August 14 report. As per Thursday, October 1, the company rating was initiated by H.C. Wainwright. The rating was initiated by Rodman & Renshaw on Friday, October 2 with “Buy”. The stock of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) earned “Outperform” rating by FBR Capital on Thursday, November 19. H.C. Wainwright maintained it with “Buy” rating and $25 target price in Tuesday, December 1 report.
According to Zacks Investment Research, “Oramed Pharmaceuticals, Inc. is a pharmaceutical company operating as a developer of oral drug delivery systems. The Company is developing orally ingestible insulin capsules for the treatment of diabetes as well as delivery solutions for other drugs and vaccines. Oramed Pharmaceuticals, Inc. is headquartered in Jerusalem, Israel.”
Insitutional Activity: The institutional sentiment decreased to 0.44 in 2016 Q2. Its down 0.42, from 0.86 in 2016Q1. The ratio turned negative, as 5 funds sold all Oramed Pharmaceuticals, Inc. shares owned while 2 reduced positions. 4 funds bought stakes while 2 increased positions. They now own 195,487 shares or 10.30% more from 177,240 shares in 2016Q1.
Ladenburg Thalmann Fincl Inc holds 0% of its portfolio in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) for 2,000 shares. Plante Moran Financial Limited Co last reported 300 shares in the company. Deutsche National Bank & Trust Ag reported 1,063 shares or 0% of all its holdings. The New York-based Jpmorgan Chase & Company has invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Barclays Pcl last reported 29,925 shares in the company. The Florida-based Finemark Retail Bank has invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Creative Planning holds 0% or 2,000 shares in its portfolio. Millennium Mgmt Llc accumulated 0% or 16,811 shares. Sunbelt Inc accumulated 290 shares or 0% of the stock. Bankshares Of America Corporation De last reported 0% of its portfolio in the stock. Wells Fargo Com Mn accumulated 8,500 shares or 0% of the stock. Pnc Grp accumulated 0% or 13,807 shares. Bank & Trust Of Montreal Can last reported 1,580 shares in the company. Fin Architects has 0.01% invested in the company for 3,450 shares. Joel Isaacson Com Ltd Limited Liability Company last reported 700 shares in the company.
More notable recent Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) news were published by: Equitiesfocus.com which released: “Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Quarterly EPS From Continuing …” on May 26, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on April 21, 2011, Quotes.Wsj.com published: “News Oramed Pharmaceuticals Inc.ORMP” on February 11, 2013. More interesting news about Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) were released by: Seekingalpha.com and their article: “Oramed Pharmaceuticals’ (ORMP) CEO Nadav Kidron Hosts Phase IIb Clinical …” published on July 29, 2016 as well as Seekingalpha.com‘s news article titled: “Oramed Vs. Novo Nordisk In Race For Oral GLP-1” with publication date: November 29, 2016.
ORMP Company Profile
Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a clinical-stage pharmaceutical company. The Firm is engaged in the field of oral delivery solutions for drugs delivered through injection. The Firm is also engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.